Terms: = Bone cancer AND FIP1L1, DKFZp586K0717, 81608, ENSG00000145216, Q6UN15 AND Prognosis
5 results:
1. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
2. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract] [Full Text] [Related]
3. [The hematological malignancies related to primary hypereosinophilia and their diagnostics].
Skonieczka K; Matiakowska K; Haus O
Postepy Hig Med Dosw (Online); 2014 Dec; 68():1530-7. PubMed ID: 25834096
[TBL] [Abstract] [Full Text] [Related]
4. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and fip1l1-PDGFRA correlates.
Tefferi A; Levine RL; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Finke CM; Mullally A; Li CY; Pardanani A; Gilliland DG
Leukemia; 2009 May; 23(5):900-4. PubMed ID: 19262599
[TBL] [Abstract] [Full Text] [Related]
5. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract] [Full Text] [Related]
